Loading clinical trials...
Loading clinical trials...
The purpose of this study is to estimate the prevalence, demographic, and clinical characteristics of PKD1/2 gene variant groups in the ADPKD population.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Vertex Pharmaceuticals Incorporated
NCT07161037 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT07454174 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06594367 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06289998 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT07181265 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Alabama Kidney Research
Alabaster, Alabama
University of Alabama at Birmingham- Nephrology Research Clinic
Birmingham, Alabama
Kaiser Permanente - Los Angeles Medical Center
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions